NYSE:MRK - Merck & Co., Inc. Stock Price, Forecast & News

$71.73

-1.80 (-2.45 %)

(As of 03/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$71.25

Now: $71.73▼

$73.43

50-Day Range

$66.40

MA: $78.95▼

$85.68

52-Week Range

$65.25

Now: $71.73▼

$92.64

Volume11.89 million shs

Average Volume18.86 million shs

Market Capitalization$181.93 billion

P/E Ratio18.83

Dividend Yield3.32%

Beta0.69

Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:MRK

Previous Symbol

CUSIP58933Y10

CIK310158

Webhttp://www.merck.com/

Phone908-740-4000

Debt

Debt-to-Equity Ratio0.87

Current Ratio1.24

Quick Ratio0.97

Price-To-Earnings

Trailing P/E Ratio18.83

Forward P/E Ratio12.54

P/E Growth1.87

Sales & Book Value

Annual Sales$46.84 billion

Price / Sales3.88

Cash Flow$6.53 per share

Price / Cash Flow10.99

Book Value$10.21 per share

Price / Book7.03

Profitability

EPS (Most Recent Fiscal Year)$5.19

Net Income$9.84 billion

Net Margins21.01%

Return on Equity49.41%

Return on Assets16.02%

Miscellaneous

Employees71,000

Outstanding Shares2,536,270,000

Market Cap$181.93 billion

Next Earnings Date4/28/2020 (Confirmed)

OptionableOptionable

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

How has Merck & Co., Inc.'s stock been impacted by COVID-19 (Coronavirus)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK stock has decreased by 9.5% and is now trading at $71.73. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Merck & Co., Inc.?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Merck & Co., Inc..

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Wednesday, February, 5th. The company reported $1.16 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.15 by $0.01. The business earned $11.87 billion during the quarter, compared to analyst estimates of $11.71 billion. Merck & Co., Inc. had a return on equity of 49.41% and a net margin of 21.01%. The business's revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.04 earnings per share. View Merck & Co., Inc.'s earnings history.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Wednesday, January 29th. Shareholders of record on Monday, March 16th will be paid a dividend of $0.61 per share on Tuesday, April 7th. This represents a $2.44 annualized dividend and a dividend yield of 3.40%. The ex-dividend date is Friday, March 13th. View Merck & Co., Inc.'s dividend history.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its board has initiated a share repurchase plan on Thursday, October 25th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its stock is undervalued.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided earnings per share guidance of $5.62-5.77 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.54. The company issued revenue guidance of $48.8-50.3 billion, compared to the consensus revenue estimate of $48.65 billion.

What price target have analysts set for MRK?

16 brokers have issued twelve-month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $84.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.60 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

What are Wall Street analysts saying about Merck & Co., Inc. stock?

Here are some recent quotes from research analysts about Merck & Co., Inc. stock:

1. Mizuho analysts commented, "We like shares of MRK driven by KEYTRUDA’s penetration of global markets in multiple indications, which we believe will drive P&L transformation. While KEYTRUDA is growing in dominance, both in the market and on MRK’s P&L, we see MRK as having considerable runway (2028 LOE) to address concerns regarding concentration of revenue." (9/8/2019)
2. According to Zacks Investment Research, "Merck’s new products like Keytruda, Lynparza, and Bridion are contributing meaningfully to the top line. Keytruda sales are gaining momentum with approval for additional indications, especially in the first-line lung cancer setting. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck. The company will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) remains a concern. Merck’s shares have outperformed the industry this year. " (4/1/2019)
3. Cantor Fitzgerald analysts commented, "We rate MRK 12-month PT of $95. We think there is upside to Keytruda sales estimates. Sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin-expansion opportunities, are underappreciated, in our view. Therefore, we expect upward earnings revisions and multiple expansion in 2019+ to drive MRK’s shares higher. Valuation Summary We arrive at our 12-month price target of $95 for Merck shares by using a blend of Base case analyses." (3/29/2019)

Has Merck & Co., Inc. been receiving favorable news coverage?

News articles about MRK stock have trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutMerck & Co., Inc..

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a decrease in short interest in March. As of March 13th, there was short interest totaling 18,162,700 shares, a decrease of 12.6% from the February 27th total of 20,780,000 shares. Based on an average trading volume of 10,770,000 shares, the short-interest ratio is currently 1.7 days. Currently, 0.7% of the shares of the stock are short sold. View Merck & Co., Inc.'s Current Options Chain.

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Bank of America (BAC).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
Mr. Adam H. Schechter, Special Advisor (Age 54)

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (4.58%), Capital World Investors (2.43%), Geode Capital Management LLC (1.57%), Capital International Investors (1.56%), Bank of New York Mellon Corp (1.37%) and Janus Henderson Group PLC (1.14%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Franklin Resources Inc., GQG Partners LLC, Victory Capital Management Inc., Bank of New York Mellon Corp, DekaBank Deutsche Girozentrale, PGGM Investments, and Pzena Investment Management LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Richard R Deluca, and Robert M Davis. View insider buying and selling activity for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Janus Henderson Group PLC, Nuveen Asset Management LLC, Renaissance Technologies LLC, Macquarie Group Ltd., Assenagon Asset Management S.A., Alliancebernstein L.P., and State Street Corp. View insider buying and selling activity for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $71.73.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $181.93 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe. View additional information about Merck & Co., Inc..

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is http://www.merck.com/.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		836 (Vote Outperform)
Underperform Votes:		824 (Vote Underperform)
Total Votes:		1,660

MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 3/28/2020 by MarketBeat.com Staff